Riskpilot← Back to searchSign inGet full accessProhisto AB
ABActiveOrg 5592040934Villtofta 3General medical practice activities · NACE 8621Est. 20190 employees
Revenue 2025
SEK 1,1M
+547% vs 2024
EBITDA margin
64.2%
+1708% vs 2024
Equity ratio
77.4%
Financial strength
Net profit 2025
SEK 577K
+664% vs 2024
| Revenue | SEK 1,1M | +547% |
| EBITDA | SEK 727K | +1708% |
| Net profit | SEK 577K | +664% |
| Total assets | SEK 810K | +66% |
| Equity | SEK 627K | +1144% |
| Employees | 0 | — |
Legal name
Prohisto AB
Org number
5592040934
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
30 april 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Konsultverksamhet med följande inriktning: histopatologiresurs inom medicinsk forskning, teknisk bedömning och expertis vid ackreditering av patologilaboratorier, undervisning, diagnostik. Dessutom ska bolaget bedriva fotografisk verksamhet samt annan därmed förenlig verksamhet. Bolaget bedriver dessutom privat läkarmottagning samt erbjuder konsultttjänster och utbildning inom hälsofrågor. Bolaget säljer kosttillskott och naturpreparat.
Address
Villtofta 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 129 | 51 | 26 | 175 | 1 133 |
| Staff expenses | — | −2 | −9 | −8 | — |
| EBITDA | 98 | 4 | −77 | −45 | 727 |
| Depreciation & amort. | −8 | −8 | −8 | −37 | −51 |
| EBIT | 90 | −4 | −84 | −83 | 676 |
| Net financials | — | −0 | −0 | −20 | 3 |
| Profit before tax | 89 | −4 | −84 | −102 | 679 |
| Tax | −19 | — | — | — | −102 |
| Net profit | 70 | −4 | −84 | −102 | 577 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 203 | 144 | 72 | 488 | 810 |
| Equity | 141 | 122 | 38 | 50 | 627 |
| Long-term debt | 0 | — | — | 440 | 0 |
| Short-term debt | 62 | 21 | 34 | −2 | 182 |
| Total debt | 62 | 21 | 34 | 438 | 182 |
EBITDA margin
64.2%
This company
15.8%
Market median
+306% vs market
20212025
Equity ratio
77.4%
This company
38.2%
Market median
+103% vs market
20212025
Return on equity
92.0%
This company
18.4%
Market median
+400% vs market
20212025
Net profit margin
50.9%
This company
8.1%
Market median
+528% vs market
20212025
Asset turnover
1.40×
This company
1.12×
Market median
+25% vs market
20212025
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Prohisto AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ute Krüger | Board of Directors | 0 companies |
| Mareike Franziska Claussen | Deputy Board Member | 0 companies |